Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment
- 17 May 2021
- journal article
- editorial
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 20 (1) , 1095-1097
Abstract
Given the prevalence of cardiovascular diseases (CVDs), as one of the most important non-communicable diseases (NCDs), the recognition of diagnostic biomarkers and potential treatment methods is very crucial. Today gut microbiota composition and its derived metabolites modification are known as one of the recent therapeutic strategies. Studies show that Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite that may be involved in the development of cardiovascular diseases, including ischemic disease and atherosclerosis, atrial fibrillation and arrhythmia, and heart failure. Due to existing some disagreements in this manner, future studies are needed to obtain a definitive sight of the association between this metabolite and CVDs. TMAO may be beneficial as a prognostic marker, which represents the degree of gut microbiota dysbiosis and subsequently CVD events and also different therapies methods based on TMAO and its metabolic pathways can be the target of clinical trial on cardiovascular disease and/or its prevention.Keywords
This publication has 16 references indexed in Scilit:
- Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic TargetNutrients, 2018
- Increased plasma trimethylamine- N -oxide is associated with incident atrial fibrillationInternational Journal of Cardiology, 2018
- l -Carnitine and heart diseaseLife Sciences, 2018
- Human Microbiome as an Approach to Personalized Medicine.2017
- Circulating trimethylamine N‐oxide and the risk of cardiovascular diseases: a systematic review and meta‐analysis of 11 prospective cohort studiesJournal of Cellular and Molecular Medicine, 2017
- Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective StudiesJournal of the American Heart Association, 2017
- Microbiota‐Dependent Metabolite Trimethylamine N‐Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA)Journal of the American Heart Association, 2016
- The Carnitine-butyrobetaine-trimethylamine-N-oxide pathway and its association with cardiovascular mortality in patients with carotid atherosclerosisAtherosclerosis, 2016
- TMAO: A small molecule of great expectationsNutrition, 2015
- Metaorganismal nutrient metabolism as a basis of cardiovascular diseaseCurrent Opinion in Lipidology, 2014